ABEOEarnings•globenewswire•
Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates
Sentiment:Positive (70)
Summary
- Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) -
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 14, 2025 by globenewswire